- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02516774
A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers (TAM-RT)
January 25, 2016 updated by: Gustave Roussy, Cancer Campus, Grand Paris
A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and radiotherapy in order to counteract tumor resistance to therapy.
Study Overview
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Val de Marne
-
Villejuif, Val de Marne, France, 94805
- Gustave Roussy Cancer Campus Grand Paris
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathologically proven anaplastic thyroid cancers (localized or metastatic)
- Life-expectancy > 12 weeks
- No previous treatment for anaplastic thyroid cancer excepted surgery or crizotinib
- Written Informed consent signed
- Age > 18 years
- WHO 0-3
- Neutrophil count > 1500 /mm3, Haemoglobin > 9 gr/dL, Platelet count > 100,000/mm3
- Bilirubin < 1.5 mg/dL, Transaminases < 3 N in absence of liver metastases or <5 N if presence of liver metastases, PT > 70%
- Creatinine clearance > 50ml/mn (calculated by the MDRD formula)
- Negative pregnancy test in women of childbearing potential within 14 days prior to treatment initiation (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization). Both men and women (of childbearing potential) who are sexually active, must use adequate contraception, during and for at least 6 months post-treatment.
- Evaluable disease > 1 cm within the cervico-mediastinal field of radiotherapy according to the Response Evaluation Criteria in Solid Tumors 1.1 criteria
- Patient affiliated to social security regimen or beneficiary of such regimen
Exclusion Criteria:
- Prior treatment with anthracyclines
- Left Ventricular Ejection Fraction (LVEF) < 50%
- Known allergy to Adalimumab, doxorubicin, cisplatin, carboplatin or paclitaxel
- Chronic or acute infection < 15 days
- Pregnant or breastfeeding patients
- Any other malignancy in the past 5 years except basal cell carcinoma and carcinoma in situ of the cervix
- Previous and/or active demyelinating disease, such as multiple sclerosis
- Prior radiotherapy to the neck
- Concomitant therapy with agents otherwise used in the treatment of cancer (for example methotrexate for rheumatoid arthritis)
- Chronic (> 3 months) treatment with oral corticosteroids or another immunosuppressant within 15 days prior registration
- Patients with an active bleeding diathesis or taking an oral vitamin K antagonist (except low-dose Coumadin (warfarin sodium))
- Other concurrent severe and/or uncontrolled disease which could compromise participation in the study (i.e. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmia, active ischemic heart disease, myocardial infarction during the previous six months, chronic liver or renal disease, active upper GI tract ulceration)
- Patient already enrolled in another therapeutic trial involving an investigational substance, and when such a substance has been taken during the previous 4 weeks
- Chronic Hepatitis B virus and previous viral hepatitis with risk of reactivation, Hepatitis C virus and human immunodeficiency virus 1 or human immunodeficiency virus 2 infection, active or latent tuberculosis infection
- Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons Refusal or absence of biopsy (excepted for initial pathological diagnosis) will not constitute an exclusion criterion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation
Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended dose
Time Frame: Up to 9 weeks
|
Two dose levels will be investigated :
|
Up to 9 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
April 29, 2015
First Submitted That Met QC Criteria
August 3, 2015
First Posted (Estimate)
August 6, 2015
Study Record Updates
Last Update Posted (Estimate)
January 26, 2016
Last Update Submitted That Met QC Criteria
January 25, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Thyroid Diseases
- Thyroid Neoplasms
- Thyroid Carcinoma, Anaplastic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Adalimumab
Other Study ID Numbers
- 2014-002618-22
- 2014/2142 (Other Identifier: CSET number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anaplastic Thyroid Cancers
-
Saint Petersburg State University, RussiaWithdrawnThyroid Gland Anaplastic CarcinomaRussian Federation
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPoorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)NRG OncologyCompletedThyroid Gland Anaplastic CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingThyroid Gland Anaplastic Carcinoma | BRAF V600K Mutation Present | BRAF NP_004324.2:p.V600EUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingLocally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaCompletedMetastatic Anaplastic Thyroid CancerUnited States
-
Saint Petersburg State University, RussiaWithdrawnPoorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 StageRussian Federation
-
M.D. Anderson Cancer CenterRecruitingThyroid Gland Anaplastic Carcinoma | Thyroid Gland Squamous Cell CarcinomaUnited States
-
University of Texas Southwestern Medical CenterNovartisWithdrawnMetastatic Anaplastic Thyroid Cancer | Locally Advanced Anaplastic, Undifferentiated Thyroid CancerUnited States
Clinical Trials on Adalimumab
-
PfizerCompletedHealthyUnited States, Belgium
-
PfizerCompletedHealthy SubjectsUnited States
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Shanghai Henlius BiotechCompleted
-
AbbottCompleted
-
Turgut İlaçları A.Ş.CompletedHealthy ParticipantsGermany
-
Mylan Inc.Mylan GmbHCompletedPsoriasis | Arthritis, PsoriaticBulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
-
AbbottCompletedRheumatoid ArthritisSpain
-
SandozHexal AGCompletedPlaque Type PsoriasisUnited States, France, Bulgaria, Slovakia